Development Of An Effective Therapy For Cheyne-Stokes Breathing In Heart Failure.
Funder
National Health and Medical Research Council
Funding Amount
$604,030.00
Summary
During sleep, patients with heart failure often exhibit a cyclic pattern of breathing in which a period of regular breathing alternates with a period when breathing ceases. This breathing pattern is associated with increased mortality and reduced quality of life but to date no effective treatment for it exists. We have developed a method to calculate an exact level of carbon dioxide to stabilise breathing in each individual, offering the prospect of a better night’s sleep and a longer life.
Targeting Complement C5a Receptor 2 As A Disease-modifying Treatment For Motor Neuron Disease
Funder
National Health and Medical Research Council
Funding Amount
$636,329.00
Summary
Motor neuron disease (MND) is a devasting terminal condition that has no effective treatment. We have identified a novel drug which inhibits an immune protein that can potentially treat MND. In this project we will test this drug in rodent models of MND, and validate its effectiveness in relevant MND immune cells. Ultimately, this project will identify a new potential drug for MND.
Formulation Of A Pan-species, Multi-stage Vaccine For The Malaria Eradication Agenda
Funder
National Health and Medical Research Council
Funding Amount
$777,611.00
Summary
GNT 1093311 entitled 'Formulation of a pan-species, multi-stage vaccine for the malaria eradication agenda' seeks to undertake the preclinical development of a saccharide conjugate vaccine directed towards all major species and stages of malaria. The objectives are: (i) to undertake the synthesis of the vaccine construct; (ii) to compare immunogenicity, formulation and efficacy of various vaccine constructs with a view to down-selecting the optimal combination to take to human clinical trial.
Harnessing Anticalin Technology As A Multi-targeted Treament Approach For Vision Loss
Funder
National Health and Medical Research Council
Funding Amount
$627,273.00
Summary
Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.